Campral Clears FDA For Alcohol Dependence: Renal Study Part Of Phase IV

Merck KGaA subsidiary Lipha will determine appropriate Campral dosing in patients with severe renal impairment as a postmarketing commitment following FDA approval of the alcoholism therapy